Stay updated on Abscopal Effect in HL Clinical Trial

Sign up to get notified when there's something new on the Abscopal Effect in HL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Abscopal Effect in HL Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or modification in the efficacy of nivolumab in patients with relapsed or refractory Hodgkin Lymphoma after anti-PD1 therapy. This change may reflect a shift in the treatment approach to improve outcomes for patients in this clinical trial.
    Difference
    0.2%
    Check dated 2024-06-06T16:04:47.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    6 days ago
    No Change Detected
  6. Check
    18 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the need for progression of refractory or relapsed cHL during treatment with an anti-PD1 agent and at least two distinct FDG-avid HL-lesions. Previously, no specific information was provided in this section.
    Difference
    13%
    Check dated 2024-05-22T12:29:34.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Summary
    The value 'Go to the classic website' has been updated to 'Site Map' on the webpage, indicating a change in the type of intervention being highlighted. This change may be related to medical and healthcare-related publications and documentation.
    Difference
    2%
    Check dated 2024-05-01T17:36:59.000Z thumbnail image

Stay in the know with updates to Abscopal Effect in HL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Abscopal Effect in HL Clinical Trial page.